Results 161 to 169 of about 5,368 (169)

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

International Journal of Cancer, 2016
Juliann Chmielecki, Laurie M Gay, Adrienne Johnson   +2 more
exaly  

Clinical Development of BRAF plus MEK Inhibitor Combinations

Trends in Cancer, 2020
Vivek Subbiah, Christina Baik, John M Kirkwood   +2 more
exaly  

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

Cancers, 2020
Ilaria Proietti, Nevena Skroza, Simone Michelini   +2 more
exaly  

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Annals of Oncology, 2015
Maria Di Bartolomeo, Alessio Amatu, C Antoniotti   +2 more
exaly  

BRAF inhibitor activity in V600R metastatic melanoma

European Journal of Cancer, 2013
Alexander M Menzies, Sandra O'Toole, Georgina V Long   +2 more
exaly  

Clinicopathologic significance ofBRAF V600E mutation in papillary carcinomas of the thyroid

Cancer, 2007
Ju-Han Lee, Young-Sik Kim
exaly  

Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases

Ca-A Cancer Journal for Clinicians
David Gritsch, Kevin S Oh, Gavin P Dunn
exaly  

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

Acta Neuropathologica, 2013
Christian Koelsche, Adelheid Woehrer, Astrid Jeibmann   +2 more
exaly  

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Aphrothiti J Hanrahan, Ziyu Chen, Neal Rosen   +2 more
exaly